Randomized multicenter trial of natalizumab in acute MS relapses: Clinical and MRI effects

Neurology

Volumn 62, Issue 11, 2004, Pages 2038-2043

  O'Connor, P W ^a   Goodman, A ^c   Willmer Hulme, A J ^d   Libonati, M A ^d   Metz, L ^b   Murray, R S ^e   Sheremata, W A ^f   Vollmer, T L ^g   Stone, L A ^h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d ELAN PHARMACEUTICALS   (United States)

^e Rocky Mountain MS Center   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g BARROW NEUROLOGICAL INSTITUTE   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; NATALIZUMAB; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISABILITY; DIZZINESS; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; HEADACHE; HUMAN; INSOMNIA; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PARESTHESIA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

EID: 2942589194     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000128136.79044.D6     Document Type: Article

References (18)

1. French-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994; 343:271-275.
2. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
3. Willoughby EW, Grochowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing subjects. Ann Neurol 1989;25:43-49.
4. Miller DH, Frank JA. Magnetic resonance imaging techniques to monitor short term evolution of multiple sclerosis and to use in preliminary trials. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S44-S46.
5. Elovaara I, Ukkonen M, Leppakynnas M, et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 2000;57:546-51.
6. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999;22:30-38.
7. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha-4 beta-1 integrin. Nature 1992;356:63-66.
8. Keszthelyi E, Karlik S, Hyduk S, et al. Evidence for a prolonged role of alpha-4 integrin throughout active experimental allergic encephalomyelitis. Neurology 1996;47:1053-1059.
9. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha-4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
11. Sipe JC, Knobler RL, Braheny SL, Rice DPA, Panitch HS, Oldstone MBA. A Neurologic Rating Scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
12. Poser CM, Porty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231.
13. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
14. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987;82:645-647.
15. Tubridy N, Behan PO, Capildo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999;53:466-472.
16. Rose AS, Kuzuma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtelotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo. Final Report 1970;20:1-59.
17. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. I. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.
18. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing-remitting multiple sclerosis. N Engl J Med 2003; 348:15-23.